THE EXPERIENCE OF INTRALESIONAL BLEOMYCIN FOR ORBITAL VASCULAR ANOMALIES
AbstractP Background: Orbital vascular anomalies are congenital and pose a challenge. They require various treatment modalities which are often unsuccessful. The use of intralesional Bleomycin has gained popularity in recent times as a scar less procedure when other treatment modalities are not effective. Purpose: To share the experience of using intra lesional Bleomycin in orbital vascular anomalies in a Tertiary care hospital. Methods: This quasi-experimental study was carried out at Layton Rahmatullah Benevolent Trust (LRBT) Teaching Tertiary care hospital, Karachi from 1st June to 31st December 2018. It included fifteen patients of various orbital vascular anomalies treated with injection of intra lesional sclerosing (Bleomycin) agent. Patients were given multiple injections and the effects of sclerosing agent on orbital vascular anomalies were observed. Results: Results were excellent in terms of regression of vascular anomalies. Conclusion: Intralesional sclerosing agent (Bleomycin) has an outstanding role in vascular tumour.
Thayal PK, Bhandari PS, Sarin YK. Comparison of Efficacy of Intralesional Bleomycin and Oral Propanolol in Management of Hemangiomas. Plast Reconstr Surg 2012;129(4):733e–5.
Enjolras O, Soupre V, Picard A. Classification of superficial vascular anomalies. 2010;39(4):457–64.
Stacey AW, Gemmete JJ, KahanaA. Management of orbital and peri-ocular vascular anomalies. Ophthalmic Plast Reconstr Surg 2015;31(6):427–36.
Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) for hemangiomas and congenital vascular malformations. Pediatr Surg Int 2004;19(12):766–73.
Ming LJ. Structure and Function of Metalloantibiotics. Med Res Rev 2003;23(6):697–762.
Ostrowski MJ. An Assessment of the Long-Term Results of Controlling the Reaccumulation of Malignant Effusions Using lntracavity Bleomycin. Cancer 1986;57(4):721–7.
Shastri S, Slayton RE, Wolter J, Perlia CP, Taylor SG 3rd. Clinical study with bleomycin. Cancer 1971;28(5):1142–6.
Pienaar C, Graham R, Geldenhuys S, Hudson DA. Intralesional Bleomycin for the Treatment of Hemangiomas. Plast Reconstr Surg 2006;117(1):221–6.
Omidvari S, Nezakatgoo N, Ahmadloo N, Mohammadianpanah M, Mosalaei A. Role of intralesional bleomycin in the treatment of complicated hemangiomas: prospective clinical study. Dermatol Surg 2005;31(5):499–501.
Muir T, Kirsten M, Fourie P. Intralesional bleomycin injection (IBI) treatment for haemangiomasand congenital vascular malformations. Pediatr Surg Int 2004;19(12):766–73.
Hill RH 3rd, Shiels WE 2nd, Foster JA, Czyz CN, Stacey A, Everman KR, et al. Percutaneous drainage and ablation as first line therapy for macrocystic and microcystic orbital lymphatic malformations. Ophthalmic Plast Reconstr Surg 2012;28(2):119–25.
Saha K, Leatherbarrow B. Orbital Lymohangiomas: a review of management strategies. Curr Opin Ophthalmol 2012;23(5):433–8.
Wiegand S, Eivazi B, Bloch LM, Zimmermann AP, Sesterhenn AM, Schulze S, et al. Lymphatic malformations of the orbit. Clin Exp Otorhinolaryngol 2013;6(1):30–5.
Gooding C, Meyer D. Intralesional bleomycin: a potential treatment for refractory orbital lymphangiomas. Ophthalmic Plast Reconstr Surg 2014;30(3):e65–7.
Yue H, Qian J, Elner VM, Guo J, Yuan Y, Zhang R, et al. Treatment of orbital vascular malformations with intralesional injection of pingyanmycin. Br J Ophthalmol 2013;97(6):739–45.
Luo QF, Zhao FY. The effects of Bleomycin A5 on infantile maxillofacial haemangioma. Head Face Med 2011;7:11.
Gelbert F, Enjolras O, Deffrenne D, Aymard A, Mounayer C, Merland J. Percutaneous sclerotherapy for venous malformation of the lips: a retrospective study of 23 patients. Neuroradiology. 2000;42(9):692–6.
Horbach SER, Rigter IM, Smitt JHS, Reekers JA, Spuls PI, van der Horst CMAM. Intralesional Bleomycin Injections for Vascular Malformations: A Systematic Review and Meta-Analysis. Plast Reconstr Surg 2016;137(1):244–56.
MacIntosh PW, Yoon MK, Fay A. Complications of intralesional bleomycin in the treatment of orbital lymphatic malformations. Semin Ophthalmol 2014;29(5-6):450–5.
Kumar V, Kumar P, Pandey A, Gupta DK, Shukla RC, Sharma SP, et al. Intralesional bleomycin in lymphangioma: an effective and safe non-operative modality of treatment. J Cutan Anesthet Surg 2012;5(2):133–6.
Wiegard S, Eivazi B, Zimmermann AP, Sesterhenn AM, Werner JA. Sclerotherapy of lymphangiomas of the head and neck. Head Neck 2011;33(11):1649–55.
Blum RH, Carter SK, Agre K. A clinical review of bleomycin -a new antineoplastic agent. Cancer 1973;31(4):903–14.
Paramivisan S, Fay A, Fifi J, Berenstein A. O-015 Image guided bleomycin sclerotherapy for orbital lymphatic malformation. J Neuro Intervent Surg 2014;6(Suppl 1):A8–9.